Rihal

AI-powered B2B procurement platform that optimizes tail spend and helps enterprises cut costs by 15-30%.

Building world-class GPUs for AI

Revibe is an online platform in the United Arab Emirates and Kingdom of Saudi Arabia that connects customers with refurbished electronic products.

Buildroid is a robotics company that develop a humanoid robot for construction purpose.

Nabta’s unique model of hybrid healthcare seamlessly combines digital health with traditional healthcare to improve health outcomes in women living with NCDs. The growing epidemic of NCDs threatens the ambition of countries around the world to achieve sustainable, universal access to health and universal health coverage for their populations. Moreover, NCDs leave populations more susceptible to communicable diseases such as coronaviruses, influenza and tuberculosis. During the COVID-19 pandemic of 2020, 78% of people admitted to ICU in the US and 94% of those who died had underlying health conditions (CDC). NCDs remain underesearched and underserved in women. Until the mid-1990s, clinical research and clinical trials largely excluded women. Only since 1994, when the United States’ National Institutes of Health (NIH) mandated that women and minorities were to be included as subjects in clinical research, has the research community entertained the fact that sex and/or gender differences might affect clinical outcomes. Today, women using drugs that were approved by the early 90s, are 50–75% more likely than men to suffer adverse reactions to those therapies. Ironically, a significant proportion of the drugs in this category are those designed to treat or manage NCDs. Examples include statins and potassium channel-blockers used to manage cardiovascular disease or hypoglycaemic drugs such as Rezulin used to control diabetes. Nabta’s first hybrid care pathway supports women in preventing, identifying and managing Polycystic Ovary Syndrome (PCOS). PCOS is a hormonal disorder responsible for 70% of female fertility issues. Women who use Nabta’s platform will be able to achieve a formal diagnosis of PCOS within 90 days. The average time taken to diagnose PCOS currently is 2.5 years.

One AI revenue engine for B2B retail; helping brands and distributors Find, Reach, and Convert buyers in one connected flow.

A2MP is dedicated to mining and unlocking Africa's mineral wealth.

eCommerce portal offering a curated collection of premium AI domain names

Helping businesses unlock the full potential of Canva.

AI-enabled accounting service

AI-powered Legal-Tech making legal research, contract drafting and analysis efficient at speed

BallsApp is a mobile sports analytics platform that uses AI-powered ball tracker to deliver real-time cricket performance insights and data.